Side Effects to Allergy Shots: Why Some People React More Than Others
Two patients on identical allergy shot protocols can have very different reaction experiences. Your individual response depends on the degree of your IgE sensitization, whether your asthma is controlled, which allergen extracts are in your vial, what medications you take, and even the time of year you receive your injection. Understanding your personal risk modifiers helps you and your allergist make smarter protocol decisions.
9 peer-reviewed sources
Individual variation in allergy shot reactions is driven by your IgE sensitization level, asthma control status, prior reaction history, allergen extract type, and seasonal allergen exposure — not random chance.
Key facts
Across 2,897 patients treated with sublingual immunotherapy via telemedicine in 2026, no cases of anaphylaxis were reported — the safety difference that allows the sublingual route to be self-administered at home, unlike injections.
Your Personal Response to Allergy Shots — Why It Differs From the Next Patient's
Population-level allergy shot reaction rates — local reactions in 26-86% of patients, systemic reactions in 0.1-0.2% of visits — tell you the average across thousands of patients. In a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015), 23,614 patients giving 2,021,600 injections had a systemic reaction rate of just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. But your individual experience is shaped by a specific set of biological, pharmacological, extract-related, and timing factors that can shift your personal risk substantially above or below those averages.
The widest range in published reaction data — local reactions from 26% to 86% — is itself evidence of how much individual variation exists. Some of this range reflects measurement differences, but a meaningful portion reflects genuine biological heterogeneity: patients with very high specific IgE concentrations react differently from those with moderate sensitization; patients with uncontrolled asthma face dramatically different risks than those with well-managed lung disease; patients on beta-blockers respond differently to systemic reactions than those without them.
Mapping your specific IgE profile is the first step in understanding where you fit on the risk spectrum. At-home allergy testing options like Curex identify your specific sensitivities across 40+ allergens, giving your allergist the data needed to predict your individual reaction pattern before the first injection is given.
This page organizes the individual risk modifiers by category — patient factors, allergen factors, protocol factors, and timing factors — so you can identify which apply to your situation.
Uncontrolled asthma is the single strongest individual risk modifier — present in 88% of immunotherapy fatalities. It is also the most modifiable: ensuring asthma control before each visit is the most impactful safety measure available.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex at-home allergy shots are clinician-supervised; confirm your current program quote before enrolling.
Join the waitlistCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
SCIT vs SLIT: Which Modality Carries Lower Individual Reaction Risk?
For patients whose individual risk profile makes weekly injection reactions a significant concern — particularly those with asthma, prior systemic reactions, or extreme IgE sensitization — understanding the systemic reaction profile of sublingual immunotherapy (SLIT) provides a clinically meaningful alternative perspective.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | Disease-modifying; significant improvement for many patients with completed therapy | 3-5 years | $3,000-10,000 with insurance | At-home self-administration with Curex — one weekly shot with brief self-observation, the first injection from each new vial or concentration supervised live in the Virtual Shot Room; individual risk factors are reviewed by your allergist before each dose change | Systemic reactions 0.1-0.2% of visits; anaphylaxis ~1/160,000; risk varies substantially by patient profile |
Sublingual Drops (SLIT) | Disease-modifying; comparable for grass, ragweed, and HDM allergens | 3-5 years, daily at home | Lower after eliminating clinic visit costs | At-home daily drops; no injection-site risk; no required commute to clinic | Systemic reactions ~0.056% of doses; ~2% of SRs severe vs ~19% SCIT; no confirmed fatalities |
Antihistamines (Daily) | Symptom control only; no disease modification or risk factor reduction | Ongoing indefinitely | $500-2,000 | Daily pill; no clinic visits | No injection risk; no IgE-mediated reaction risk |
- Efficacy
- Disease-modifying; significant improvement for many patients with completed therapy
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-10,000 with insurance
- Convenience
- At-home self-administration with Curex — one weekly shot with brief self-observation, the first injection from each new vial or concentration supervised live in the Virtual Shot Room; individual risk factors are reviewed by your allergist before each dose change
- Safety
- Systemic reactions 0.1-0.2% of visits; anaphylaxis ~1/160,000; risk varies substantially by patient profile
- Efficacy
- Disease-modifying; comparable for grass, ragweed, and HDM allergens
- Duration
- 3-5 years, daily at home
- Cost (5yr)
- Lower after eliminating clinic visit costs
- Convenience
- At-home daily drops; no injection-site risk; no required commute to clinic
- Safety
- Systemic reactions ~0.056% of doses; ~2% of SRs severe vs ~19% SCIT; no confirmed fatalities
- Efficacy
- Symptom control only; no disease modification or risk factor reduction
- Duration
- Ongoing indefinitely
- Cost (5yr)
- $500-2,000
- Convenience
- Daily pill; no clinic visits
- Safety
- No injection risk; no IgE-mediated reaction risk
For patients whose individual risk profile — asthma, prior reactions, or beta-blocker use — makes weekly clinic visits hard to sustain, Curex delivers the allergy shot at home: a personalized SCIT serum sterile-compounded to USP <797> standards, self-administered as one weekly injection with pricing confirmed in a current program quote. A board-certified allergist reviews your risk factors to confirm candidacy, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room — addressing the same allergen triggers as in-clinic SCIT on the same gradual escalation.
Join the waitlistThe Four Categories of Individual Risk Modifiers
Individual variation in allergy shot reactions arises from four categories of modifiable and non-modifiable factors. Patient factors relate to your underlying health conditions and medications. Allergen factors relate to the properties of the specific extracts being injected. Protocol factors relate to how your build-up schedule is designed. Timing factors relate to when in the year your injections occur relative to your specific allergen's peak season. The key insight from the research is that no single factor operates in isolation. A patient with well-controlled asthma, no prior systemic reactions, moderate IgE sensitization, a conventional build-up schedule, and winter injections has a very different risk profile than a patient with poorly controlled asthma, prior systemic reactions, extremely high specific IgE, a cluster protocol, and spring injections during peak pollen season. Your allergist's job is to identify your risk modifier profile before designing your protocol. Data sources: Bernstein 2004 (JACI; fatality survey); Epstein 2013 (Ann Allergy; Year 3 risk-factor analysis); Roy 2007 (Ann Allergy); REPEAT Study Calabria 2011 (Ann Allergy); Tversky 2022 (JACI); Lockey 1987 (JACI).
Uncontrolled asthma is the dominant individual risk modifier for severe allergy shot reactions. Of 41 confirmed fatalities in the Bernstein 2004 JACI fatality survey, 88% involved patients with asthma, most suboptimally controlled. Pre-existing airway hyperreactivity amplifies the bronchospastic response to allergen-triggered mast cell mediators. The 2011 Practice Parameter requires peak-flow assessment before each injection for asthmatic patients, and injections should not be given when asthma is uncontrolled. Prior systemic reaction history is the strongest individual-level predictor of future reactions: Roy 2007 (Ann Allergy) found a four-fold higher systemic reaction rate on subsequent injections in patients with prior SR history. Beta-blocker use is not an automatic exclusion, but requires individualized provider review and enhanced informed consent — beta-blockers impair epinephrine's bronchodilatory effect and may worsen anaphylaxis management; the 2023 Anaphylaxis Practice Parameter (Golden et al., Ann Allergy) supports shared decision-making when cardiac indications are compelling.
Ensure asthma is well-controlled (FEV1 >70% predicted) before each injection. Avoid peak-flow assessment days when your asthma is flaring. Inform your allergist immediately if you start or stop beta-blockers or ACE inhibitors.
The properties of the allergen extract itself influence individual reaction risk. Protease-rich allergens — mold (Alternaria, Cladosporium) and cockroach — contain enzymes that can degrade other allergens when co-mixed in multi-allergen vials. This degradation reduces the effective dose of non-protease allergens in the vial, potentially causing unexpected potency variation. Patients on multi-allergen vials containing mold or cockroach may encounter unpredictable extract activity over time. Additionally, new vial transitions consistently appear in reaction surveillance as a risk-elevation event: batch-to-batch potency variation means a 'same dose' from a fresh vial may not be pharmacologically identical to the one from the previous vial. The 2011 Practice Parameter recommends a 50-75% dose reduction when transitioning to a new extract vial. The degree of specific IgE sensitization also matters: patients with very high IgE concentrations for the target allergen carry more primed mast cells and may respond more strongly to the same dose.
Inform your allergist each time a new vial is started. Expect a dose reduction at new-vial transitions. If you are on a multi-allergen vial containing mold, ask your allergist whether a separate mold vial might reduce interaction effects.
The schedule by which doses are increased during build-up directly determines per-injection systemic reaction rates. Conventional build-up (one injection per visit, doses increasing weekly) carries a systemic reaction rate of approximately 0.2% per injection (Cox 2011 Practice Parameter). Cluster build-up (2-4 injections per visit to reach maintenance faster) carries roughly three times the per-injection systemic reaction rate: Tversky 2022 (JACI; n=91) found 0.69% standard vs 2.29% cluster (IRR 3.3; 95% CI 1.5-7.3). A multicenter cluster cohort reported 10.9% per-patient systemic reaction rate. Rush protocols have historically shown even higher rates but can be mitigated with antihistamine and corticosteroid premedication (Portnoy 1994). Recurrent large local reactions also indicate elevated individual risk: the REPEAT Study (Calabria 2011, Ann Allergy) found 41.7% systemic reaction rate in patients with frequent LLRs versus 10.7% without. A single isolated LLR, however, is not predictive (Tankersley 2000, JACI).
Patients with prior systemic reactions, uncontrolled asthma, or very high specific IgE should discuss whether cluster or rush protocols are appropriate for their risk profile. Antihistamine premedication is standard for accelerated schedules.
The time of year significantly affects individual reaction risk for patients sensitized to seasonal allergens. Natural allergen exposure during pollen season upregulates tissue mast cells, eosinophils, and adhesion molecules systemically — so the same maintenance dose administered in January may provoke a larger response in April during peak grass pollen season. Year 3 AAAAI/ACAAI surveillance data (Epstein 2013, Ann Allergy) showed practices consistently reducing doses during peak pollen season had significantly fewer Grade 2-3 systemic reactions (44% vs 65% of events, p=0.04). Historically, 41% of allergy shot fatalities occurred during the patient's relevant pollen season (Lockey 1987, JACI). The standard clinical approach: proactively reduce maintenance dose by approximately 50% at the start of peak season and increase back to maintenance gradually over the following months. In-season injections should not be skipped — continued exposure during build-up and maintenance is important for efficacy — but doses should be adjusted.
Proactively inform your allergist of your peak allergy season. Expect dose reduction at the start of each pollen season. If you miss injections during pollen season and return to full maintenance dose immediately, contact your allergist to discuss dose step-down first.
When to Worry: Decision Guide
Do you have asthma, a prior systemic reaction history, or are you on beta-blockers?
Elevated individual risk — discuss with allergist
Your allergist should assess asthma control before each injection, review your medication list, and may recommend a slower build-up schedule, premedication, or extended post-injection monitoring.
Standard individual risk
Follow standard protocol: 30-minute observation, self-monitor at home for 2-4 hours after each injection. Report any systemic symptoms immediately.
Are you starting a new extract vial or entering your relevant pollen season?
Transient elevated risk period
Inform your allergist before the injection. Expect a dose reduction at new-vial transition or at pollen season onset. These are routine protocol adjustments, not cause for alarm.
Routine maintenance visit
Standard 30-minute observation. Continue self-monitoring protocol at home.
Frequently asked questions
Why do some patients have severe allergy shot reactions while others have none?
Severe allergy shot reactions are not random — they cluster in patients with identifiable risk factors. The most important is uncontrolled asthma, which was present in 88% of confirmed immunotherapy fatalities in the Bernstein 2004 JACI fatality survey. Pre-existing airway hyperreactivity amplifies the bronchospastic component of systemic reactions and reduces the respiratory reserve needed to compensate. A prior systemic reaction history increases future systemic reaction risk approximately four-fold (Roy 2007, Ann Allergy). Very high specific IgE concentrations for the target allergen, beta-blocker use, cluster or rush build-up protocols, and peak pollen season exposure all further modify individual risk. Patients without any of these risk factors — with well-controlled asthma (or no asthma), no prior reactions, on conventional build-up, not in pollen season — are at the lowest end of the risk spectrum.
Does having a strong local reaction mean I'll have a systemic reaction next time?
A single large local reaction at one injection visit does not reliably predict a systemic reaction at the next visit. The 2011 AAAAI/ACAAI Practice Parameter Third Update explicitly states this, citing the LOCAL Study (Calabria 2009, JACI) and Tankersley 2000 as supporting evidence. A no-dose-adjustment policy after isolated large local reactions was not associated with increased systemic reaction rates in controlled studies. However, the picture is more nuanced when reactions are recurrent. The REPEAT Study (Calabria 2011, Ann Allergy) found that 41.7% of patients with frequent recurrent large local reactions experienced at least one systemic reaction during follow-up, compared to 10.7% of patients without recurrent reactions. The practical guidance: report recurrent large local reactions to your allergist — the pattern matters, not the isolated event.
Does my age affect how I react to allergy shots?
Age itself is not established as an independent risk factor for allergy shot reactions, but comorbidities that cluster with age — particularly cardiovascular disease, asthma, and polypharmacy including beta-blockers — do increase individual risk. Older patients are more likely to be on beta-blockers for cardiac indications, which impairs epinephrine's rescue effect during anaphylaxis. A 2023 review by Bozek (Curr Opin Allergy Clin Immunol) confirmed high safety of allergen immunotherapy in patients over 60 for grass, birch, and dust mite allergens, with the dominant practical concern being comorbidity management rather than age per se. Pediatric patients, on the other hand, tend to have fewer cardiovascular comorbidities but may have less precise asthma monitoring, making age-related risk considerations essentially a question of comorbidity burden rather than calendar age.
Why does pollen season increase my reaction risk?
During your relevant pollen season, your immune system is continuously being exposed to the same allergens you are being treated for in your allergy shots. This ongoing natural exposure upregulates tissue mast cells, eosinophils, and adhesion molecules throughout the respiratory mucosa and skin — a process called allergen priming. When you then receive an allergy shot containing those same allergens, the primed mast cells respond more vigorously to the same dose, increasing the probability of both local and systemic reactions. Year 3 AAAAI/ACAAI surveillance data (Epstein 2013, Ann Allergy) confirmed that practices reducing doses during peak season had 21 percentage points fewer Grade 2-3 reactions. The message: peak pollen season does not mean skipping injections (that actually disrupts the desensitization process), but it does mean temporarily reducing the dose.
Are patients on beta-blockers at higher risk for allergy shot reactions?
Beta-blocker use is not an automatic exclusion from allergy shots, but it requires individualized provider review and enhanced informed consent. Beta-blockers impair epinephrine's bronchodilatory and cardiovascular effects, meaning a patient who experiences anaphylaxis may respond less well to standard epinephrine doses and may require glucagon (1-5 mg IV) as an alternative rescue agent. More recent venom immunotherapy data (Müller & Haeberli 2005, JACI; Stoevesandt 2014, Clin Exp Allergy) found no increased reaction frequency or severity in beta-blocker users, and the 2023 Anaphylaxis Practice Parameter (Golden et al., Ann Allergy) supports shared decision-making when cardiac indications are compelling. Patients on beta-blockers should discuss their specific situation with both their cardiologist and allergist before starting immunotherapy.
Does it matter which allergens are in my allergy shot?
Yes — the specific allergen composition of your extract affects both efficacy and reaction risk. Protease-rich allergens such as mold (Alternaria, Cladosporium) and cockroach contain enzymes that can degrade other allergens when mixed in the same vial, potentially creating unpredictable extract potency over the vial's shelf life. Patients on multi-allergen vials containing these proteases may experience reactions at doses that were previously well-tolerated as the extract composition changes over time. Your allergist may separate these allergens into distinct vials to prevent degradation. Additionally, some allergens have a narrower window between therapeutic and reaction-inducing doses than others, which affects the rate of dose escalation during build-up. Knowing your complete allergen sensitization profile helps your allergist optimize vial composition for both safety and efficacy.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreAllergy Immunotherapy Side Effects: SCIT & SLIT | Curex
Allergy immunotherapy side effects: SCIT systemic rate 0.1-0.2% per visit; SLIT 0.056% per dose, zero confirmed fatalities. Full SCIT vs SLIT comparison.
Read moreSide Effects of Allergy Immunotherapy | Clinical Overview
Allergy immunotherapy adverse events: SCIT local 26-86%, systemic 0.1-0.2%. SLIT oral-local 40-75%, systemic 0.056%, zero fatalities. Clinical overview.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT retrains the immune system over 3–5 years and is the only disease-modifying allergy treatment; many patients get long-term relief that can persist after treatment.
Read moreAllergy Shot Side Effect Rates: Frequency Data | Curex Guide
Allergy shot side effect rates from 54M visits: local reactions 26-86%, systemic 0.1-0.2%, anaphylaxis 1/160,000. Every rate with its source denominator.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.